All In MedTech

Device Trial Radar · NCT04750889

Breast Localization: RFID Tags vs Wire Localization

RFID Trial: Localization of Non-palpable Breast Lesions Using Radiofrequency Identification Tags or Wire

Last checked: Nov 19, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

May 15, 2021

Primary completion

Apr 24, 2023

Study completion Apr 24, 2023

Sponsor

Lead sponsor
Centre Jean PerrinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 11, 2021

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The RFID trial focuses on breast localization in patients with non-palpable breast cancers. It aims to demonstrate the improvement in patient comfort when using the Radio Frequency Identification (RFID) tag and LOCalizer™ device compared to the gold standard device.

Conditions

  • Breast Neoplasm Female

Interventions

  • RFID tagsDevice

    Installation of the RFID tag device wire localization)

  • Wire localizationDevice

    Installation of the wire localization device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of the patients satisfactionTime frame: 1 years and 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre Jean PERRIN

    Clermont-Ferrand, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.